{"disease":{"id":"gastrointestinal-cancer-metastatic","name":"gastrointestinal cancer metastatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00068003","title":"Harvesting Cells for Experimental Cancer Treatments","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06445062","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1130,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT00788957","title":"Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"NantBioScience, Inc.","has_results":true},{"nct_id":"NCT03597581","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT04534543","title":"MAESTRO Study: Metabolic Imaging to Improve Patient-Specific Therapy Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT04298489","title":"Drug Sensitivity Screening for Gastrointestinal Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05837767","title":"A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02293954","title":"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05087992","title":"A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03343301","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05359042","title":"Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT04105062","title":"LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06690281","title":"A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}